7 Unknown Biotech Stocks That Could Rocket in 2023 Investing in early-stage or unknown biotech stocks can be likened to investing in cryptocurrency projects. If the project developments are positive, returns can be multi-folds in a short time. Similarly, biotech stocks can skyrocket on the commercialization of potential blockbuster drugs. With the covid-19 pandemic, investments have surged in the biotechnology sector. As the research pipeline for various conditions deepens, the investment opportunities continue to expand. My view is underscored by the point that venture capitalists have pumped $35 billion into biotech companies between 2019 and 2021. This column focuses on seven unknown biotech stocks that can be potential multi-baggers. Most of these biotech companies are still in the clinical stage of drug development. This implies high risk. However, a sub-portfolio of clinical-stage biotech stocks can be rewarding even if there are few promising stories. Let’s look at the reasons that make these unknown biotech stocks interesting.